Executive Summary
On January 13, 2026, NASDAQ-100 filings showed a cluster of routine 8-K disclosures dominated by neutral financial results and Reg FD updates from healthcare players like Acadia Healthcare and ACADIA Pharmaceuticals, alongside vague 'other events' in tech names. Standout risks include Estrella Immunopharma's high-materiality delisting notice and Intuitive Machines' opaque M&A, financial obligations, and equity sales, introducing bearish biotech pressures and high-uncertainty transactional activity. Overall low materiality suggests minimal sector-wide disruption to NDX, but flags isolated alpha shorts and M&A catalysts amid earnings season kickoff.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from January 11, 2026.
Investment Signals(4)
- ▲
Notice of delisting and failure to satisfy listing standards [BEARISH] - Estrella Immunopharma
- ▲
Entry into material agreements and asset acquisition/disposition [BULLISH] - Intuitive Machines
- ▲
Results of operations and Reg FD disclosures signaling earnings visibility [BULLISH] - Acadia Healthcare, ACADIA Pharmaceuticals
- ▲
Low-risk other events indicating operational stability [BULLISH] - Broadcom, Artificial Intelligence Technology Solutions
Risk Flags(4)
- ▼
Delisting event with transfer risk eroding shareholder value [HIGH] - Estrella Immunopharma
- ▼
Undisclosed M&A details, off-balance sheet obligations, and unregistered equity sales [HIGH] - Intuitive Machines
- ▼
Pervasive lack of quantitative metrics across filings impairing transparency and assessment
- ▼
Potential compliance failures in biotech amid listing pressures
Opportunities(4)
- ◆
Short Estrella Immunopharma pre-delisting for compliance-driven downside
- ◆
Long Intuitive Machines on potential M&A synergies once deal terms disclosed
- ◆
Healthcare earnings alpha via deep-dive into Acadia Healthcare and ACADIA Pharmaceuticals exhibits for beats
- ◆
Stable tech longs in Broadcom/AI Tech Solutions amid low-materiality routine updates
Sector Themes(3)
- ◆
Healthcare earnings cluster with Reg FD focus from Acadia Healthcare and ACADIA Pharmaceuticals signaling Q4 reporting momentum
- ◆
Biotech delisting risks amid compliance challenges, as seen in Estrella Immunopharma
- ◆
Tech/space transactional uptick with M&A and obligations at Intuitive Machines, events at Broadcom/AI Tech
Watch List(4)
- 👁
Estrella Immunopharma - Delisting progression, transfer details, and liquidity impacts
- 👁
Intuitive Machines - M&A parties, valuations, financial obligations, and equity dilution effects
- 👁
Acadia Healthcare & ACADIA Pharmaceuticals - Full earnings metrics, guidance, and peer correlations
- 👁
Broadcom - Clarification on undisclosed other events for strategic implications
Filing Analyses(6)
13-01-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001493152-26-001931, Size: 221 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, financial statements, or exhibits are disclosed. Sector is not specified.
13-01-2026
Acadia Healthcare Company, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001437749-26-001137, Size: 2 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, revenue, earnings, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.
13-01-2026
Intuitive Machines, Inc. filed an 8-K on January 13, 2026 (AccNo: 0001193125-26-011200, Size: 467 KB), disclosing entry into a material definitive agreement (Item 1.01), completion of acquisition or disposition of assets (Item 2.01), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), unregistered sales of equity securities (Item 3.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). No specific details on deal structure, parties involved, valuation, consideration, or strategic rationale are provided in the filing summary. All quantitative metrics such as transaction value, share counts, and financial impacts are NOT_DISCLOSED.
13-01-2026
ACADIA PHARMACEUTICALS INC filed a Form 8-K on January 13, 2026 (AccNo: 0001193125-26-011706, Size: 163 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.
13-01-2026
Broadcom Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001193125-26-011731, Size: 613 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, or exhibits are disclosed in the provided filing summary. Sector not specified.
13-01-2026
Estrella Immunopharma, Inc. filed a Form 8-K on January 13, 2026 (AccNo: 0001213900-26-003998, Size: 241 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This discloses a delisting event from the US market. Sector not specified.
Get daily alerts with 4 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 6 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC